Latest Thalidomide Stories
By CHRIS MALLETT A Teenage music-lover who has been treated for cancer for nearly six years has taken singing lessons with an international gospel choir, thanks to a children's charity.
Velcade is likely to receive EMEA approval following a positive opinion issued by the EU Committee for Medicinal Products for Human Use for use in previously untreated multiple myeloma patients.
Proteolix has started patient dosing in a Phase Ib clinical trial to evaluate the safety and efficacy of Proteolix's lead anticancer agent, carfilzomib, in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma.
SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Proteolix, Inc.
New Indication Provides Treatment-Free Interval As an Option Media: International Myeloma Foundation Peggy Frank, 818-735-3591 Logo: http://myeloma.org/ The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today applauded the decision by the US Food and Drug Administration (FDA) to expand the benefits of VELCADE(R) (bortezomib) for injection to a wider range of multiple...
Celgene Corporation David Gryska, 908-673-9059 Sr. Vice President and Chief Financial Officer or Brian P.
Vion Pharmaceuticals has reported positive data from a previously conducted Phase II trial of its lead anticancer agent Cloretazine in elderly patients with acute myelogenous leukemia and high-risk myelodysplastic syndromes.
Celgene International Sarl (Nasdaq:CELG) announced that data presented today at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark found that patients previously treated for multiple myeloma receiving REVLIMID (lenalidomide) in combination with dexamethasone experienced a significant survival gain regardless of the number of prior therapies they had received.
Celgene International Sarl (Nasdaq:CELG) today announced that according to data from a pooled study presented at the 13th European Hematology Association (EHA) congress in Copenhagen, Denmark, multiple myeloma patients taking REVLIMID(R) (lenalidomide) plus dexamethasone significantly increased their survival rates.
ATLANTA (Reuters) - Celgene Inc.'s cancer drug Revlimid improves the rate of survival in previously treated patients with the blood cancer multiple myeloma by at least a year compared with those taking standard treatment, according to data released on Monday.
- A mania for the use of printing-types; a strong propensity to write for publication.